Liu, Si-Yang

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 959

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 440

Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer

Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 228

Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 85

Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival

Jee, J., Fong, C., Pichotta, K., Tran, T., Luthra, A., Altoe, M., Maron, S., Shen, R., Liu, S.-Y., Waters, M., et al. (2023) · Cancer Research

Lung Cancer Treatments and MutationsRadiomics and Machine Learning in Medical Imaging

Cited by 4